Emcure

Ref: EPL/CS/SE/0097/2026 **Date:** November 05, 2026

To,

National Stock Exchange of India Limited **Exchange Plaza, C-1, Block G,** **Bandra Kurla Complex, Bandra (East),** **Mumbai – 400 051** **Script Symbol: EMCURE**	**BSE Limited** **P J Towers,** **Dalal Street,** **Mumbai- 400 001** **Scrip Code/Symbol: 544210/ EMCURE**

Dear Sir/Madam,

Subject: Newspaper Publication of Unaudited Financial Results of the Company for the quarter and half-year ended September 30, 2026.

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith extracts of the Unaudited Financial Results of the Company for the quarter and half-year ended September 30, 2026, as published in the newspapers viz. "Financial Express" and "Loksatta" on November 04, 2026.

The above-mentioned extracts of Newspaper Publication are also being uploaded on the website of the Company i.e. www.emcure.com.

You are requested to take the above information on your records.

Thanking you,

For **Emcure Pharmaceuticals Limited**

AMRUTA AMIT YANGALWAR
Digitally signed by AMRUTA AMIT YANGALWAR
Date: 2026.11.05 10:16:23 +05'30'

Amruta Yangalwar
Company Secretary & Compliance Officer
ICSI Membership Number: A25687

Emcure®

EMCURE PHARMACEUTICALS LIMITED

Registered and Corporate Office: Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune - 411 057, Maharashtra, India.
Tel: +91 20 3507 0033, +91 20 3507 0000; E-mail: investors@emcure.com; Website: www.emcure.com
Corporate Identity Number: L24231PN1981PLC024251

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026

(₹ in Million)

Sr. No.	Particulars	Quarter ended			Half year ended		Year ended
		30-Sep-26	30-Jun-26	30-Sep-25	30-Sep-26	30-Sep-25	31-Mar-26
1	Total Revenue from operations	28,204.71	25,804.47	22,698.22	54,009.18	43,703.59	92,035.40
2	Net Profit before tax	4,458.52	3,935.26	3,414.17	8,393.78	6,321.75	12,871.43
3	Net Profit after tax	3,250.68	2,924.93	2,513.70	6,175.61	4,661.63	9,412.69
4	Total Comprehensive Income	3,393.06	3,131.64	2,794.71	6,524.70	5,738.38	11,073.91
5	Paid up equity share capital [Face value per share: ₹10]	1,897.11	1,896.82	1,895.65	1,897.11	1,895.65	1,895.90
6	Other equity (as shown in the audited Balance Sheet)						47,604.42
7	Earnings per share (not annualised for the Quarter ended):						
	Basic (in ₹)	17.16	15.50	12.85	32.67	23.77	48.77
	Diluted (in ₹)	17.14	15.50	12.85	32.63	23.77	48.77

The key information of the Standalone Financial results of the Company are given below:

(₹ in Million)

Sr. No.	Particulars	Quarter ended			Half year ended		Year Ended
		30-Sep-26	30-Jun-26	30-Sep-25	30-Sep-26	30-Sep-25	31-Mar-26
1	Total Revenue from operations	16,679.84	14,509.31	12,606.04	31,189.15	23,571.77	52,431.88
2	Net Profit before tax	3,323.76	2,686.73	1,578.91	6,010.49	3,235.60	9,441.91
3	Net Profit after tax	2,484.28	2,001.08	1,176.22	4,485.36	2,404.11	7,329.59
4	Total Comprehensive Income	2,483.16	1,999.95	1,173.97	4,483.11	2,399.62	7,336.09

Notes:

1. The above Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on November 03, 2026.
2. The above is an extract of the detailed format of the Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026 filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of these Financial Results are available on the Stock Exchange websites, www.bseindia.com and www.nseindia.com and on the Company's website www.emcure.com.

For EMCURE PHARMACEUTICALS LIMITED

Sd/-
Satish Mehta
Managing Director & CEO
DIN: 00118691

Place: Pune
Date: 03 November, 2026

Emcure®

EMCURE PHARMACEUTICALS LIMITED

Registered and Corporate Office: Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune - 411 057, Maharashtra, India.
Tel: +91 20 3507 0033, +91 20 3507 0000; **E-mail:** investors@emcure.com; **Website:** www.emcure.com
Corporate Identity Number: L24231PN1981PLC024251

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026

(₹ in Million)

Sr. No.	Particulars	Quarter ended			Half year ended		Year ended
		30-Sep-26	30-Jun-26	30-Sep-25	30-Sep-26	30-Sep-25	31-Mar-26
1	Total Revenue from operations	28,204.71	25,804.47	22,698.22	54,009.18	43,703.59	92,035.40
2	Net Profit before tax	4,458.52	3,935.26	3,414.17	8,393.78	6,321.75	12,871.43
3	Net Profit after tax	3,250.68	2,924.93	2,513.70	6,175.61	4,661.63	9,412.69
4	Total Comprehensive Income	3,393.06	3,131.64	2,794.71	6,524.70	5,738.38	11,073.91
5	Paid-up equity share capital [Face value per share: ₹10]	1,897.11	1,896.82	1,895.65	1,897.11	1,895.65	1,895.90
6	Other equity (as shown in the audited Balance Sheet)						47,604.42
7	Earnings per share (not annualised for the Quarter ended):						
	Basic (in ₹)	17.16	15.50	12.85	32.67	23.77	48.77
	Diluted (in ₹)	17.14	15.50	12.85	32.63	23.77	48.77

The key information of the Standalone Financial results of the Company are given below:

(₹ in Million)

Sr. No.	Particulars	Quarter ended			Half year ended		Year ended
		30-Sep-26	30-Jun-26	30-Sep-25	30-Sep-26	30-Sep-25	31-Mar-26
1	Total Revenue from operations	16,679.84	14,509.31	12,606.04	31,189.15	23,571.77	52,431.88
2	Net Profit before tax	3,323.76	2,686.73	1,578.91	6,010.49	3,235.60	9,441.91
3	Net Profit after tax	2,484.28	2,001.08	1,176.22	4,485.36	2,404.11	7,329.59
4	Total Comprehensive Income	2,483.16	1,999.95	1,173.97	4,483.11	2,399.62	7,336.09

Notes:

1. The above Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on November 03, 2026.
2. The above is an extract of the detailed format of the Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026 filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of these Financial Results are available on the Stock Exchange websites, www.bseindia.com and www.nseindia.com and on the Company's website www.emcure.com.

For **EMCURE PHARMACEUTICALS LIMITED**

Sd/-
Satish Mehta
Chairman, Managing Director & CEO
DIN: 00118691

Place: Pune
Date: 03 November, 2026